Ubs Asset Management Americas Inc Revance Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $417 Billion
  • Q4 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 237,409 shares of RVNC stock, worth $610,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares
237,409
Previous 265,210 10.48%
Holding current value
$610,141
Previous $681,000 10.43%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
N/A
-27,801 Reduced 10.48%
237,409 $610,000
Q3 2024

Nov 14, 2024
BUY
$2.57 - $2.57 $70,469 - $70,469
27,420 Added 11.53%
265,210 $681,000
Q2 2024

Aug 13, 2024
BUY
$2.34 - $4.73 $277,123 - $560,169
118,429 Added 99.22%
237,790 $611,000
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $50,465 - $97,283
8,686 Added 7.85%
119,361 $1.05 Million
Q3 2023

Nov 13, 2023
BUY
$11.47 - $25.07 $226,658 - $495,408
19,761 Added 21.74%
110,675 $1.27 Million
Q1 2023

May 15, 2023
BUY
$18.36 - $35.27 $218,998 - $420,700
11,928 Added 15.1%
90,914 $2.93 Million
Q4 2022

Feb 14, 2023
BUY
$18.32 - $30.66 $168,012 - $281,182
9,171 Added 13.14%
78,986 $1.46 Million
Q3 2022

Nov 14, 2022
BUY
$14.33 - $28.47 $14,086 - $27,986
983 Added 1.43%
69,815 $1.89 Million
Q2 2022

Aug 12, 2022
BUY
$11.52 - $20.4 $34,571 - $61,220
3,001 Added 4.56%
68,832 $951,000
Q4 2021

Feb 14, 2022
SELL
$12.46 - $27.87 $3.7 Million - $8.27 Million
-296,717 Reduced 81.84%
65,831 $1.07 Million
Q3 2021

Nov 15, 2021
SELL
$25.78 - $33.21 $199,691 - $257,244
-7,746 Reduced 2.09%
362,548 $10.1 Million
Q2 2021

Aug 16, 2021
SELL
$26.8 - $31.84 $371,501 - $441,366
-13,862 Reduced 3.61%
370,294 $11 Million
Q1 2021

May 14, 2021
BUY
$24.03 - $29.97 $227,804 - $284,115
9,480 Added 2.53%
384,156 $10.7 Million
Q4 2020

Mar 01, 2021
BUY
$23.41 - $28.34 $7.78 Million - $9.42 Million
332,453 Added 787.37%
374,676 $10.6 Million
Q3 2020

Nov 13, 2020
BUY
$23.23 - $34.3 $29,920 - $44,178
1,288 Added 3.15%
42,223 $1.06 Million
Q2 2020

Aug 14, 2020
BUY
$12.6 - $26.55 $73,974 - $155,875
5,871 Added 16.74%
40,935 $999,000
Q1 2020

May 15, 2020
BUY
$12.46 - $27.81 $61,041 - $136,241
4,899 Added 16.24%
35,064 $518,000
Q4 2019

Feb 14, 2020
BUY
$11.66 - $20.15 $187,469 - $323,971
16,078 Added 114.13%
30,165 $489,000
Q3 2019

Nov 14, 2019
BUY
$10.22 - $14.5 $10,782 - $15,297
1,055 Added 8.1%
14,087 $183,000
Q1 2019

May 14, 2019
BUY
$15.4 - $20.39 $200,692 - $265,722
13,032 New
13,032 $0

Others Institutions Holding RVNC

# of Institutions
208
Shares Held
80.9M
Call Options Held
2.26M
Put Options Held
5.48M
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email